Dyne Therapeutics, Inc. $DYN Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC trimmed its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 64.0% during the second quarter, Holdings Channel reports. The fund owned 300,074 shares of the company’s stock after selling 534,102 shares during the quarter. Squarepoint Ops LLC’s holdings in Dyne Therapeutics were worth $6,665,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Nykredit A S purchased a new position in Dyne Therapeutics in the second quarter valued at about $113,000. California State Teachers Retirement System grew its stake in Dyne Therapeutics by 2,049.2% during the 2nd quarter. California State Teachers Retirement System now owns 3,001,615 shares of the company’s stock valued at $66,666,000 after purchasing an additional 2,861,952 shares in the last quarter. Moore Capital Management LP increased its holdings in Dyne Therapeutics by 288.2% during the 2nd quarter. Moore Capital Management LP now owns 305,794 shares of the company’s stock worth $6,792,000 after purchasing an additional 227,029 shares during the last quarter. Two Sigma Securities LLC purchased a new stake in Dyne Therapeutics during the 2nd quarter worth approximately $222,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Dyne Therapeutics in the 2nd quarter valued at approximately $5,448,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of DYN opened at $18.42 on Friday. Dyne Therapeutics, Inc. has a 52 week low of $11.92 and a 52 week high of $27.31. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. The firm has a market cap of $3.44 billion, a price-to-earnings ratio of -5.53 and a beta of 1.08. The stock has a 50 day moving average of $24.68 and a 200-day moving average of $20.54.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, analysts forecast that Dyne Therapeutics, Inc. will post -3.51 EPS for the current year.

Dyne Therapeutics News Roundup

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Morgan Stanley reaffirmed its Buy rating on Dyne, signaling continued confidence in the company’s pipeline and long-term outlook. Morgan Stanley reaffirmed Buy rating
• Positive Sentiment: RBC maintained an Outperform rating, saying Dyne’s DM1 approach remains differentiated, although it reduced its price target from $35 to $30. Investors are also awaiting additional six- and 12-month data for DYNE-101 and topline results from the fully enrolled ACHIEVE expansion cohort, expected in the first quarter of 2027. RBC assessment of Dyne’s DM1 approach
• Neutral Sentiment: Unusually heavy call-option activity was reported, with roughly 20,532 calls traded versus average daily volume of about 464. The activity may indicate speculative expectations for a rebound or clinical-data catalyst, but it does not establish improving fundamentals. Unusually large options trading in DYN
• Neutral Sentiment: Reported short interest was zero shares, implying no meaningful short-selling position or days-to-cover exposure based on the figures provided. This is unlikely to be a major near-term trading catalyst.
• Negative Sentiment: JPMorgan downgraded DYN from Neutral to Underweight and cut its price target from $17 to $10. The move followed a rival DM1 therapy’s Phase 3 failure, which raised concerns about clinical and commercial risks across the disease class. JPMorgan downgrade following Novartis setback
• Negative Sentiment: An insider sold 900 shares for approximately $21,915, reportedly to cover tax withholding tied to vested equity awards. The sale was small relative to the insider’s remaining holdings, limiting its fundamental significance, but it may add modestly to cautious sentiment. Dyne insider stock sale

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, insider Douglas Kerr sold 3,745 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $24.35, for a total transaction of $91,190.75. Following the completion of the sale, the insider owned 163,854 shares in the company, valued at $3,989,844.90. The trade was a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Cox sold 5,658 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total transaction of $106,823.04. Following the sale, the chief executive officer directly owned 357,507 shares in the company, valued at $6,749,732.16. This trade represents a 1.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 4,150,974 shares of company stock worth $99,697,629 in the last ninety days. 9.46% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on DYN shares. Royal Bank Of Canada reduced their target price on Dyne Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday. Cantor Fitzgerald initiated coverage on shares of Dyne Therapeutics in a research note on Thursday, July 23rd. They issued an “overweight” rating for the company. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a report on Friday, May 15th. TD Cowen assumed coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. Finally, Wall Street Zen lowered shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $32.17.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.